Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Clin Transl Oncol. 2022 Dec;24(12):2295-2304. doi: 10.1007/s12094-022-02910-y. Epub 2022 Aug 16.
Colorectal cancer (CRC) is a malignant tumor initiating from the mucosa of the colorectum. According to the 2020 statistics from the World Health Organization, there are 10.0% CRC cases among all 19.3 million new cancers, followed by lung and breast cancer, and 9.4% CRC cases among all 9.9 million cancer deaths, ranking second. The population of CRC patients in China is large, and its incidence and mortality continue to increase each year. Despite the continuous development of surgical methods, chemotherapy, radiotherapy, targeted therapy and immunotherapy, the overall survival of CRC patients remains low. Past research has suggested that c-myc plays a pivotal role in the development of CRC. A higher expression level of c-Myc is a negative prognostic marker in CRC. However, there are few drugs targeting c-myc directly. Therefore, we focused on discovering the mechanism of c-myc in CRC to provide a reference for a better therapy choice for patients.
结直肠癌（CRC）是一种起始于结直肠黏膜的恶性肿瘤。根据世界卫生组织 2020 年的统计数据，CRC 在所有新发癌症中占 10.0%，仅次于肺癌和乳腺癌，在所有癌症死亡中占 9.4%，排名第二。中国结直肠癌患者数量庞大，其发病率和死亡率呈逐年上升趋势。尽管手术方法、化疗、放疗、靶向治疗和免疫治疗不断发展，但 CRC 患者的总体生存率仍然较低。过去的研究表明，c-myc 在 CRC 的发展中起关键作用。c-Myc 表达水平较高是 CRC 的一个负预后标志物。然而，直接针对 c-myc 的药物很少。因此，我们专注于发现 c-myc 在 CRC 中的作用机制，为患者提供更好的治疗选择提供参考。
